Reuters logo
6 months ago
BRIEF-Omeros reports additional positive results from OMS721 Phase 2 trial
March 1, 2017 / 12:14 PM / 6 months ago

BRIEF-Omeros reports additional positive results from OMS721 Phase 2 trial

March 1 (Reuters) - Omeros Corp

* Omeros reports additional positive results from OMS721 phase 2 trial in patients with stem cell transplant-associated thrombotic microangiopathy

* Omeros Corp - total of ten serious adverse events have been reported, none considered related to OMS721 treatment

* Omeros Corp - two patients died of progression of cancer after less than three weeks of OMS721 treatment

* Omeros Corp - one patient died of graft failure after completing study and positively responding to oms721

* Omeros Corp - none of these deaths was considered by investigators to be related to OMS721 treatment. Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below